Euronext sees investors moving money to Europe in US rethink

European stocks have outperformed those in the US this year amid concern that tariffs imposed by Washington will weigh on growth in the world’s largest economy
Euronext sees investors moving money to Europe in US rethink

Euronext CEO Stéphane Boujnah: 'We are facing a de facto stimulus program in Europe, driven by massive investments coming in infrastructure'. File Picture: euronext.com

Euronext CEO Stéphane Boujnah said investors are increasingly moving money to Europe amid prospects for higher government spending and as investors re-evaluate the US markets.

The Trump administration's policies in the US have created “massive volatility”, accelerating a flow of funds globally to Europe where valuations remain cheaper, Mr Boujnah said in an interview on Bloomberg TV.

“Trump’s policies have injected massive volatility in the market, in particular with the hesitation on tariffs every day,” Mr Boujnah said.

“There is a fundamental rethinking of investing in the US for European firms, because it is becoming a fundamentally different country.”

European stocks have outperformed those in the US this year amid concern that tariffs imposed by Washington will weigh on growth in the world’s largest economy.

Upcoming vote

While a trade war with the US would create a “lose-lose situation”, the money flow into Europe has been accelerated by the prospect of massive stimulus, Mr Boujnah said.

Lawmakers in Germany were scheduled to vote on a bill on Tuesday that would unlock hundreds of billions of euros in debt-financed defence and infrastructure spending, heralding a pivot toward a substantially more expansive fiscal policy.

“We are facing a de facto stimulus program in Europe, driven by massive investments coming in infrastructure,” Mr Boujnah said.

Europe still remains cheap and there are further upsides to come through for European equities

Mr Boujnah said he is optimistic that IPOs would rebound along with markets, and that some firms that were considering a US listing are re-evaluating their plans.

Stada Arzneimittel AG’s private equity owners are pushing back a planned IPO of the German drugmaker due to market volatility, people familiar with the matter have said.

  • Bloomberg

More in this section

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited